Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)
Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-Guerin (BCG)
  • Phase

    Phase 2/Phase 3
  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    valrubicin ...
  • Study Participants

This is a Phase II/Phase III study of intravesical AD 32 (valrubicin) in patients with carcinoma in situ (CIS) who have been previously treated with intravesical Bacillus Calmette-Guerin (BCG) for CIS and in whom recurrence or failure has occurred after multiple courses of intravesical treatment.
Study Started
Nov 30
Primary Completion
Apr 30
Study Completion
Apr 30
Last Update
Jun 12

Drug Valrubicin, 800 mg

Investigator will be responsible for regulating the use of concomitant medications (systemic and/or topical anticholinergic therapy or topical anesthesia) and other medications.

AD32 (valrubicin) Experimental

800mg, once weekly for 6 weeks



Patients must have pathologically-proven CIS with no evidence of muscle invasive disease.
Patients with concurrent Ta or T1 papillary tumors are eligible provided papillary tumor(s) are resected prior to study treatment. Cystoscopic evaluation and, if indicated, transurethral resection of bladder tumor (TURBT) must be performed within 28 days of study treatment.
Patients must have received at least two or more prior courses of intravesical therapy for CIS per the recommended schedules. BCG must have been one of the prior therapies administered. Patients can have either failed BCG therapy or have been successfully treated with BCG, but subsequently found to have recurrence. The standard course of intravesical therapy must include six weekly treatments (allowable range of instillations per course is 4-9).
Patients must have a positive urine cytology at baseline (<28 days) prior to the first AD 32 (valrubicin) treatment. Patients with papillary lesions must have a positive cytology following TURBT or have a baseline cytology that was negative or equivocal and histologic confirmation of CIS.
Patients must have an ECOG performance status of 0-2 and a life expectancy of at least 6 months.


Patients with urogenital tumors with histology other than transitional cell carcinoma
Patients with residual papillary disease at the time of study treatment.
Patients with a history of other primary malignancy (other than squamous or basal cell skin cancers) within the last 5 years.
Patients with evidence of muscle invasive disease (stage higher than T1).
Patients with any previous intravesical treatment with AD 32 (valrubicin).
Patients with any intravesical therapy within 28 days prior to first AD 32 (valrubicin) treatment.
Patients with a plan to receive other concurrent therapy for treatment of primary treatment tumor during participation in this study.
Patients who had received prior systemic or radiation therapy for bladder cancer.
Women who were pregnant or lactating. Individuals of reproductive potential could not participate unless agreeing to use an effective contraceptive method for themselves and/or their sexual partners.
Patients who, in the investigator's opinion, could not comply with the provisions of the protocol or did not understand the nature of the study.
Patients who, in the opinion of the investigator, could not tolerate intravesical administration of approximately 75 mL of fluid or who could not tolerate surgical manipulation (cystoscopy, mapping biopsies, barbotage) due to the presence of concomitant serious illnesses (ie, uncontrolled cardiac or respiratory disorders).
No Results Posted